Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma Journal Article
| Author: | Meyers, P. A. |
| Article Title: | Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma |
| Abstract: | Osteosarcoma is an ultraorphan disease. There are approximately 1000 new patients diagnosed with osteosarcoma each year in the USA and Europe. Current treatment for osteosarcoma utilizes multiagent chemotherapy and surgical resection of all clinically detectable disease. Current treatments for osteosarcoma achieve 60-70% event-free survival (EFS) for patients with localized disease and approximately 20% EFS for patients who present with metastasis. These results have been stable for two decades. The addition of muramyl tripeptide (mifamurtide) to chemotherapy resulted in a trend towards improved EFS and a one-third reduction in the risk of death from osteosarcoma. Mifamurtide has been approved in Europe for the treatment of newly diagnosed osteosarcoma in combination with chemotherapy. © 2009 Expert Reviews Ltd. |
| Keywords: | osteosarcoma; cancer chemotherapy; event free survival; cancer surgery; unclassified drug; clinical trial; fatigue; review; cisplatin; doxorubicin; fluorouracil; interferon; placebo; hypertension; nonhuman; recommended drug dose; side effect; drug approval; methotrexate; drug megadose; cancer diagnosis; cancer incidence; technetium 99m; anorexia; metastasis; anemia; bone marrow suppression; etoposide; gastrointestinal symptom; nausea; thrombocytopenia; vomiting; myalgia; weight reduction; bisphosphonic acid derivative; drug structure; ifosfamide; monoclonal antibody; somatomedin c receptor; abdominal pain; arthralgia; asthenia; backache; chill; coughing; dyspnea; fever; sarcoma; europe; hypotension; malaise; rigor; drug distribution; add on therapy; folinic acid; diclofenac; ibuprofen; nonsteroid antiinflammatory agent; thrombocyte count; drug clearance; blood pressure; flu like syndrome; drug absorption; muramyl tripeptide; mammalian target of rapamycin inhibitor; risk reduction; leg pain; tachycardia; liposome; zoledronic acid; immunostimulator; mifamurtide; dipalmitoylphosphatidylethanolamine; bronchospasm; hyperventilation; nervousness; pericarditis; pleurisy; pulse rate; respiratory tract disease |
| Journal Title: | Expert Review of Anticancer Therapy |
| Volume: | 9 |
| Issue: | 8 |
| ISSN: | 1473-7140 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2009-08-01 |
| Start Page: | 1035 |
| End Page: | 1049 |
| Language: | English |
| DOI: | 10.1586/era.09.69 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 3" - "Export Date: 30 November 2010" - "CODEN: ERATB" - "Source: Scopus" |
